Nightingale Health Plc has received five new patents from the Finnish Patent and Registration Office. Nightingale Health announced during 2023 that it had received nine patents, and with these five new patents the company's patent portfolio expands to cover additional health areas such as infectious diseases and anemia. The first of the newly received patents was granted for the company's proprietary technology's ability to determine whether an individual is at risk of developing a musculoskeletal and/or connective tissue disease such as osteoarthritis.

The second patent was granted for the ability to determine whether an individual is at risk of developing an infectious disease or a complication thereof. The third patent was granted for the ability to determine whether an individual is at risk of developing anemia. The fourth and fifth patents were granted for the ability to determine whether an individual is at risk of developing a metabolic condition related to nutritional state or fluid balance.

Understanding and managing these conditions is important for maintaining health and preventing chronic diseases. The patents increase the value of the company's intellectual property assets. In addition to the patents granted in Finland, the company has several international patent applications pending.